Open AccessRetrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers
Author(s) -
Poorni Manohar,
Lauren J. Beesley,
Jeremy M. G. Taylor,
Elizabeth Hesseltine,
Megan R. Haymart,
Nazanene H. Esfandiari,
David A. Hanauer,
Francis P. Worden
Publication year - 2015
Publication title -
journal of thyroid disorders and therapy
Language(s) - English
Resource type - Journals
ISSN - 2167-7948
DOI - 10.4172/2167-7948.1000188
Subject(s) - sirolimus , hazard ratio , medicine , cyclophosphamide , population , urology , oncology , everolimus , gastroenterology , chemotherapy , confidence interval , environmental health
We hypothesize that the combination of an mTOR inhibitor, sirolimus, with a well-known cytotoxic agent, cyclophosphamide, provides a well-tolerated and promising alternative treatment for advanced, differentiated thyroid cancers (DTC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom